Cancer Care Specialists | Oncology and Hematology Department

Research site

Location

5423 Reno Corporate Drive, Reno, Nevada, United States of America

Website

https://www.ccsreno.com/

Site insights

Top conditions

Top treatments

EloPd

Golcadomide

Alisertib

SPd

Zongertinib

Selinexor

Doxorubicin Hydrochloride

Bevacizumab

Sorafenib Tosylate

Elotuzumab

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Contact this site

Mari Toumaian

Verified by this site

Active trials

9 of 17 total trials

A Phase 3 Study of Rusfertide in Patients With Polycythemia Vera (VERIFY)

The study is designed to evaluate the safety and efficacy of rusfertide in subjects with polycythemia vera (PV) in maintaining hematocrit control and...

Active, not recruiting

Polycythemia Vera

Drug: Placebo

Drug: Rusfertide

A Single-arm, Multicenter Study to Assess the Efficacy, Safety, and Tolerability of P1101 in Adults With ET

A Single-arm, Multicenter Study to Assess the Efficacy, Safety, and Tolerability of Ropeginterferon alfa-2b-njft (P1101) in Adult Patients with Essen...

Active, not recruiting

Essential Thrombocythemia

Drug: Ropeginterferon alfa-2b-njft (P1101)

A Study Investigating the Efficacy and Safety of LBL-007 Plus Tislelizumab in Combination With Bevacizumab Plus Fluoropyrimidine Versus Bevacizumab Plus Fluoropyrimidine in Participants With Unresectable or Metastatic Colorectal Cancer

This is a Phase 1b/2 study to investigate the efficacy and safety of LBL-007 plus tislelizumab when administered in combination with bevacizumab plus...

Active, not recruiting

Unresectable or Metastatic Microsatellite Stable/Mismatch Repair Proficient Colorectal Cancer

Drug: Capecitabine

Drug: Tislelizumab

A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer (ALISCA-Breast1)

PUMA-ALI-1201 is a randomized, dose optimization, multicenter, Phase 2 study of alisertib administered in combination with endocrine therapy in parti...

Enrolling

Hormone Receptor Positive HER-2 Negative Breast Cancer

Metastatic Breast Cancer

Drug: Alisertib

Drug: Endocrine therapy

A Study of Combination of Selinexor, Pomalidomide, and Dexamethasone (SPd) Versus Elotuzumab, Pomalidomide, and Dexamethasone (EloPd) in Subject With Previously Treated Multiple Myeloma

This phase 3 randomized, open-label multicenter trial will compare the efficacy, safety and the impact on health-related quality of life (HR-QoL) of...

Enrolling

Multiple Myeloma

Drug: Selinexor

Drug: Elotuzumab

A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment

The purpose of this study is to learn about the safety and how effective the study medicine (PF-07220060) plus fulvestrant is compared to the study d...

Active, not recruiting

Advanced or Metastatic Breast Cancer

Drug: Everolimus

Drug: Fulvestrant

Beamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment

This study is open to adults 18 years and older with advanced or metastatic non-small cell lung cancer. People can join the study if they have tumour...

Enrolling

Lung Cancer, Non-squamous, Non-small Cell

Drug: carboplatin

Drug: pemetrexed

Phase 3 Study of Pelabresib (CPI-0610) in Myelofibrosis (MF) (MANIFEST-2)

A Phase 3, randomized, blinded study comparing pelabresib (CPI-0610) and ruxolitinib with placebo and ruxolitinib in myelofibrosis (MF) patients that...

Active, not recruiting

Myelofibrosis

Post-essential Thrombocythemia Myelofibrosis

Drug: Placebo

Drug: Pelabresib

Locations recently updated

Study to Compare the Effectiveness and Safety of Golcadomide Plus R-CHOP vs Placebo Plus R-CHOP in Participants With Previously Untreated High-risk Large B-cell Lymphoma (GOLSEEK-1)

The purpose of this study is to compare the effectiveness and safety of golcadomide in combination with rituximab, cyclophosphamide, doxorubicin, vin...

Enrolling

Large B-cell Lymphoma

Drug: Golcadomide

Drug: Doxorubicin